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Introduction
The European Lead Factory (ELF) is a major Innovative 
Medicines Initiative (IMI)–funded project aiming to dis-
cover and develop novel chemical structures for drug dis-
covery programs in the public and private sectors.1 To 
achieve this aim, a Joint European Compound Library 
(JECL) has been established by combining approximately 
300,000 mostly proprietary compounds from participating 
pharmaceutical companies, with up to 200,000 additional 
bespoke compounds designed and synthesized during the 
course of the project, based on contributed ideas from 
around Europe.2 European academics and small and 
medium-sized enterprises (SMEs) are eligible to submit tar-
get proposals to the ELF, and following a review process, 
successful programs are scheduled to be screened against 
the entire library within the European Screening Centre 
(ESC), primarily based in Scotland and the Netherlands. 
One of the major deliverables of the ELF is the provision of 
a qualified hit list (QHL) of 50 or fewer hit structures to the 
academic or SME submitter of the target. They then gain 
the rights to exploit the compounds on the QHL as chemical 
starting points for drug discovery programs or as tools for 
investigating and validating novel pharmacological targets. 
The nomination of the QHL represents an irreversible 
decision gate, at which point the legal rights and obligations 
are committed to eliminating the possibility of mining for 
alternative hit structures if later investigations invalidate the 
compounds as not developable.3 It is therefore of critical 
importance to use a range of tools and techniques in a high-
throughput screening (HTS) workflow that minimizes the 
chance of this least desirable of outcomes.4
A well-designed screening workflow, also known as a 
screening cascade, should be bespoke for every target and 
consists of a series of assays through which compounds are 
tested that maximizes the likelihood of identifying genuine 
binders of the target while minimizing the risk of selecting 
undesirable compounds. These undesirable compounds, 
sometimes referred to as nuisance compounds or pan-assay 
interference compounds (PAINS),5 have been reviewed 
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Perspective
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Abstract
High-throughput screening (HTS) is a proven method for discovering new lead matter for drug discovery and chemical 
biology. To maximize the likelihood of identifying genuine binders to a molecular target, and avoid wasting resources 
following up compounds with unproductive/nonspecific mechanisms of action, it is important to employ a range of assays 
during an HTS campaign that build confidence of target engagement for hit compounds. Biophysical methods that measure 
direct target/compound engagement have established themselves as key techniques in generating this confidence, and 
they are now integral to the latter stages of HTS triage at the European Lead Factory (ELF). One relatively new technique 
that the ELF is using is microscale thermophoresis (MST), which measures the differences in rate of movement through a 
temperature gradient that are caused when single molecular species form complexes. Here we provide an overview of the 
MST assay development workflow that the ELF employs and a perspective of our experience to date of using MST to triage 
the output of HTS campaigns and how it compares and contrasts with the use of other biophysical techniques.
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extensively elsewhere,4–8 with different targets/assays being 
sensitive to different mechanisms of interference, and 
include fluorescent or colored compounds that disrupt the 
assay readout,9,10 redox cycling compounds,11 aggrega-
tors,12 metal chelators,13 DNA or RNA intercalators,14 and 
metal contaminants.15 The probability of misidentifying 
these undesirable compounds as genuine hits is reduced by 
introducing deselection assays into the screening cascade, 
which should identify compounds exhibiting the undesir-
able behaviors that the target/assay is sensitive to. Such 
compounds are probably not meaningfully interacting with 
the target and are therefore deprioritized or dismissed from 
further selection, but that does not eliminate the possibility 
that they may still be meaningfully binding to the target. A 
more satisfactory approach is, where possible, to adopt a 
positive selection strategy in the form of one or more 
orthogonal assays that aim to confirm on-target activity, yet 
are different enough from the primary assay that they are 
likely to have a different profile of sensitivity to nuisance 
compounds. Most compound screens against isolated pro-
tein targets involve the use of a microplate-based biochemi-
cal assay, which is relatively cheap and reliable and can be 
performed on a scale required for HTS. Typically, these 
involve a probe acting as a surrogate of the physiological 
function of the target and are almost always light based, 
being monitored with a multilabel plate reader via some 
form of fluorescence, absorbance, or luminescence. Using 
an orthogonal biochemical assay with a probe complemen-
tary to that used in the primary assay (i.e., fluorescence 
rather than absorbance, ideally at differing wavelengths) is 
a good way of rapidly following up on large numbers of hits 
to eliminate those that interfere with the primary assay tech-
nology. However, many nuisance compounds disrupt the 
protein function or structure rather than simply interfere 
with the signal, and so tend to be active in both assays. An 
alternative, complementary, and increasingly adopted 
approach in the latter stages of HTS is the use of biophysi-
cal assays.16,17 These assays probe the nature of the direct 
interactions between ligands and proteins rather than rely-
ing on the functional activity of the protein. Most biophysi-
cal techniques are still relatively low throughput, and 
therefore not amenable to primary screening, but can play a 
very important role in HTS triaging to confirm target 
engagement of hits, validate their selection for further opti-
mization, and inform structure–activity relationships 
(SARs).18–20
Use of Biophysics in the European 
Lead Factory
A wide range of biophysical methods are available to mea-
sure the affinity of ligand–protein interactions. Each tech-
nique provides a range of different information on the 
binding specificity, stoichiometry, kinetics, and/or thermo-
dynamics of binding interactions, with their own advan-
tages and disadvantages, which have been reviewed 
extensively elsewhere.17–19,21 Unlike label-based biochemi-
cal assays, most biophysical assays tend to involve fewer 
assay components, making them less prone to compound 
interference or aggregation.19 Many are also applicable to a 
wide range of target classes and are not reliant on monitor-
ing target function, so the assessment of binding interac-
tions does not require an enzyme to be active, or even for 
the function of the target to be known, and compound bind-
ing can be measured regardless of their mechanism of 
action (i.e., agonists, antagonists, activators, or inhibitors).
No single biophysical technique appears to be more reli-
able than any other as a hit triaging tool, with different 
methods having been shown to identify different popula-
tions of hits from the same screen.22–24 For this reason, if 
possible, a number of techniques are best used in combina-
tion to provide the most comprehensive assessment of tar-
get binding for hits from an HTS campaign. The choice of 
technology is driven by consideration of various factors, 
ranging from assay sensitivity and ligand and protein mate-
rial requirements to the availability of in-house equipment 
and expertise (see Renaud et al. for an excellent review 
summarizing the pros and cons of the most commonly 
applied technologies17). The ELF manages a very busy 
project portfolio of >80 distinct targets and operates at a 
throughput of 15–20 ultra-high-throughput screens per 
year, meaning that there is a balance to be struck with the 
amount of time and resources that can be invested in each 
project. The portfolio of targets is diverse and represents all 
major target classes, consisting of enzymes (58%), trans-
porters (1%), receptors (7%), ion channels (6%), protein–
protein interactions (15%), protein–DNA interactions (4%), 
protein–RNA interactions (2%), and a variety of other tar-
gets with a diversity of functions (8%). This includes pro-
teins ranging from 20 kDa up to >1 MDa in size, and often 
the amount of target protein for individual targets is limited, 
in terms of both the quantity that can be supplied and the 
number of different constructs that are available. We also 
have to operate with very stringent compound usage restric-
tions, whereby we are limited to 5.5 µL of 10 mM DMSO 
stock to follow up hits in the primary, deselection, selectiv-
ity (if required), and biochemical and biophysical orthogo-
nal assays. Despite these limitations, we still aim to employ 
more than one biophysical method to identify positive hits 
and have adopted three complementary techniques: surface 
plasmon resonance (SPR), microscale thermophoresis 
(MST) and thermal shift assay (TSA; also known as differ-
ential scanning fluorimetry [DSF]). The strict reagent 
restrictions make techniques such as isothermal titration 
calorimetry (ITC) and nuclear magnetic resonance (NMR) 
impractical.
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Microscale Thermophoresis
MST is emerging as a sensitive method that can be used to 
assess biomolecular interactions25–29 and has been utilized to 
study interactions between a variety of binding partners of 
various molecular sizes: protein–protein, antibody–antigen, 
protein–DNA, and protein–RNA interactions and the binding 
of ligand to ternary complexes.26–28 The use of MST is increas-
ingly being reported in fragment-based drug discovery,23,24,30–33 
including kinases such as p38α30 and MEK1,31 and the bromo-
domain BRD9.32 In both the MEK1 study by Sanofi in collabo-
ration with NanoTemper and the BRD9 study by Boehringer 
Ingelheim, MST was used to confirm the binding of fragments 
identified by SPR and DSF, as well as to identify additional hits 
not detected by the other techniques. Pollack et al. compared 
the binding affinity of a handful of fragments to p38α mea-
sured by MST and other assays, such as SPR, mobility shift 
assay, and a fluorescence lifetime assay, and found good 
agreement across these different technologies.30 Unlike fluo-
rescence polarization (FP) or reporter displacement assays, 
where one might fail to identify binding to allosteric sites, 
as the test compounds need to compete for binding with a 
fluorescent tracer, MST allows the quantitative measurement 
of the direct binding affinity of a compound to the target, 
enabling the detection of binding to orthosteric and allosteric/
cryptic sites.34–36 This may explain the broad applicability of 
the technique and how additional hits are identified using 
direct binding methods.24 However, if required, MST assays 
can be designed to perform competition experiments with a 
reference ligand.26
MST measures the interaction between biomolecules in 
solution. Thermophoresis, also known as the Ludwig–Soret 
effect, is defined as the direct movement of molecules through 
a temperature gradient.37,38 A molecule’s thermophoretic prop-
erties are determined by charge, size, and hydration shell.27 
Upon binding to some interacting partner, one or more of these 
three parameters may be altered, resulting in a change in its 
thermophoretic movement.26 Measuring changes in thermo-
phoresis can then allow for the quantification of the affinity of 
the interaction between the binding partners. There is the 
potential for complementary, conflicting, or confounding 
influences on the three key parameters, which makes it diffi-
cult to predict the magnitude of effect, if any, that the formation 
of a given complex will have on thermophoretic movement. 
The suitability of MST as a technique for assessing target–
ligand interactions must therefore be assessed on a case-by-
case basis with careful assay development. To monitor the 
thermophoresis of biomolecules, the Monolith instruments 
commercialized by NanoTemper use an infrared (IR) laser, 
which heats an aqueous sample loaded in a thin glass capillary. 
The laser focus produces a localized microscopic temperature 
gradient with a heat range of 2–6 °C, and ligand–target protein 
complexes demonstrate a different movement velocity through 
the temperature gradient compared with unbound molecules. 
This movement through the laser-heated spot is monitored via 
fluorescence of the target protein, either from the intrinsic UV 
fluorescence of tryptophan, tyrosine, and phenylalanine resi-
dues (tryptophan exhibiting the strongest fluorescence) or 
from labeling the protein with a fluorescent dye through cova-
lent attachment to lysine or cysteine residues,27 or noncovalent 
attachment to a polyhistidine tag.39 Rapid scanning of a series 
of capillaries containing a constant concentration of fluores-
cent target molecule and increasing concentrations of ligand 
enables the determination of equilibrium binding constants. 
Alternatively, the ligand can be fluorescently labeled and the 
unlabeled protein titrated.
Unlike technologies such as SPR, which rely on detect-
able changes in size or mass triggered by a binding event, 
variations in the thermophoretic profile can be caused by 
minute changes in the target molecule’s solvation entropy, 
even in the absence of changes to the protein’s size or 
charge.26 Binding interactions between very small ligands 
and large proteins are therefore detectable, as shown by 
Wienken et al. with the binding of calcium ions with a 
molecular weight of 40 to the 16.7 kDa calmodulin protein, 
corresponding to a molecular ratio of 417.5.25 This explains 
why MST is gaining popularity as a technique for fragment 
screening, because it allows the study of weak-affinity frag-
ments titrated up to 10 mM.31,32 In addition, MST is 
described as offering a wide detection range, from low- 
millimolar to picomolar affinities, when using NanoTemper’s 
dedicated Monolith NT.115Pico instrument.28 In general, dis-
sociation constants (Kd) within twofold of the protein con-
centration can be accurately quantified.27 One of the greatest 
advantages of MST in an ELF context is that it works with 
very low amounts of ligand and dye-labeled target.26,27 
Although the Monolith NT.Automated instrument can only 
accommodate 96 capillaries per run, in our experience the 
short measurement times of 15–25 s per capillary enable 
rapid screening of at least 800 samples per day. MST allows 
the measurement of molecular interactions in solution, 
avoiding the need to immobilize proteins to surfaces and 
reducing the observation of nonspecific compound binding 
to coupling chemistries, which can sometimes complicate the 
analysis when using techniques such as SPR.40 Furthermore, 
MST is reported to work in both simple, common buffers 
and more complex biological systems, such as cell lysates 
and serum.27,28,41 It can also be used with solubilized pro-
teins and proteins in liposomes, as shown in a study on 
SNARE proteins.26
MST as a Tool in the European Lead 
Factory
Currently, there are no published reports on the use of MST 
as a triage tool for HTS, but we have found that the technol-
ogy is adaptable for use at a number of different stages in the 
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ELF screening workflow (Fig. 1). The low sample require-
ments and applicability to a wide range of proteins make 
MST an ideal technology when considering the diversity of 
the ELF portfolio and the strict sample limitations. We have 
used MST as an orthogonal assay to inform triage decisions 
and progress hits from primary screens; however, the 
throughput is such that we find it is not ideal for triaging 
many thousands of potential hits. A strategy that can be 
employed to increase the throughput is the testing of all com-
pounds at a single concentration, as described for a fragment 
screen by Martin et al.32 We have investigated this approach 
with tens of compounds, following up the statistically signifi-
cant actives as full dose–response curves, but have concerns 
about the high false-positive and -negative rates we observed, 
as will be discussed later. More typically, we use computa-
tional selection of representative hits from structural clusters, 
together with interesting singletons, to reduce the number of 
hits from a screen to the low hundreds, allowing us to test all 
compounds at multiple concentrations. We also use MST to 
provide detailed characterization of hit molecules following 
release of the QHL, and for the testing of new analogs syn-
thesized by the ESC Medicinal Chemistry group for affinity 
ranking and providing SAR. Usefully, MST can often also 
identify false positives and the mechanism by which they 
interfere, such as photobleaching, photoenhancement, and 
autofluorescence (apparent in the magnitude and shape of the 
MST trace), and aggregation (apparent as irregular bumpy 
traces).31,42 The MST assay optimization procedure is usually 
rapid and the analysis of binding interactions and determina-
tion of binding affinities (Kd or EC50) simple. We have estab-
lished a stepwise workflow to developing MST assays and 
screening hit compounds (Fig. 2), which involves the 
optimization of several key parameters. The following is a 
description of the workflow and how the data are interpreted 
and presented to the project teams.
Choice of MST Labeling Approach and 
Coupling Chemistry
The first assay development step is to choose the detection 
method. The two main MST approaches are label-free MST, 
measuring intrinsic UV protein fluorescence, and labeled 
MST, where the protein is coupled to a longer-wavelength 
fluorescent dye. The Monolith NT.Automated instrument can 
be fitted with up to four channels to detect UV, blue, green, 
and red fluorescence of proteins at nanomolar concentrations 
or the fluorescence of red dye–labeled proteins at picomolar 
concentrations (if the picodetector is installed). This diversity 
of detectors allows for the measuring of commonly used dyes 
and fluorescent proteins, such as GFP, TAMRA, Cy5, and 
fluorescein. Our instrument is fitted with the UV detector and 
the nanodetector for blue and red fluorescence, which pro-
vided us with the widest range of available detection 
options. Any commercially sourced dye covering the requi-
site fluorescence wavelengths is suitable for labeling pro-
teins. Common coupling chemistries include thiol-reactive 
maleimide-linked dyes for the labeling of cysteine residues 
and amine-reactive N-hydroxysuccinimide (NHS)-linked 
dyes for lysine labeling.27 Recently, a red fluorescent dye was 
released by NanoTemper containing a tris-nitrilotriacetic acid 
(NTA) moiety for noncovalent coupling to polyhistidine 
tags.39 These dyes often come as kits, including gravity-flow 
size-exclusion desalting columns, to buffer exchange the tar-
get protein if its storage buffer comprises components 
Figure 1. Typical screening cascade for an ELF program. Targets are screened at a single concentration of 10 µM, followed by 
confirmation of activity again at 10 µM. Deselection, orthogonal, or selectivity assays are used to prioritize promising hits before 
confirming their potency in the primary assay. A maximum of 100 compounds are selected for liquid chromatography–mass 
spectrometry (LC-MS) analytical assessment, and up to 55 compounds undergo a final intellectual property clearance before selection 
of the QHL, comprising up to 50 compounds. For promising programs, hit validation and optimization can lead to an improved hit list 
(IHL). MST can be used at various stages of the triage process (indicated by red arrows).
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incompatible with the chosen coupling chemistry. For 
instance, free amine containing buffers such as Tris or gly-
cine will compete for coupling to the NHS dye, or buffers 
containing high concentrations of imidazole will disrupt the 
binding between the nickel(II) ions of the tris-NTA dye and 
the protein polyhistidine tag.43,44
The choice between label-free (280 nm excitation, 350 
nm emission) or labeled (blue: 493 nm excitation, 521 nm 
emission; green: 557 nm excitation, 574 nm emission; red: 
650 nm excitation, 670 nm emission) MST is influenced by 
the project requirements. We prefer to use the red dyes, as 
many screening compounds and reference molecules inter-
fere at UV wavelengths;9 however, our experience is that 
dye modification of proteins can disrupt their structure and 
function, sometimes limiting this option. Structural knowl-
edge of the target protein therefore provides very useful 
insight. For example, cysteine labeling should be avoided 
for proteins with known disulfide bridges critical to their 
structural integrity. Similarly, reactive dyes should be used 
with caution for proteins containing active-site cysteines or 
lysines, as this may result in steric hindrance, affecting the 
binding of orthosteric ligands and yielding an inaccurate Kd 
value, or completely ablating binding. Some effort can be 
taken to vary the dye–protein stoichiometry and/or labeling 
time to reduce the population of active-site blocked protein 
molecules or try to mask active-site residues by including 
reference ligands during the coupling process, but our suc-
cess with this technique has so far been limited.
The approach of noncovalent His tag labeling offers an 
attractive alternative when the ligand binding site on the 
protein is known to contain critical cysteine or lysine resi-
dues or has not yet been characterized. It is also a very con-
venient approach within the ELF because most proteins are 
supplied by the submitter of the target, and in the majority 
of cases, these proteins contain a 6xHis tag. One issue to be 
aware of, however, is the potential for hit compounds to 
appear as false positives through an interaction with the 
label/His tag and not a binding site on the protein. To con-
trol for this, the NanoTemper labeling kit includes a peptide 
with a 6xHis tag that can be labeled to assess the interaction 
of the ligand with the tag or tris-NTA dye. When possible, it 
is recommended to compare the affinity estimates of a ref-
erence ligand measured using both label-free and labeled 
MST approaches. When this is not an option, for example, 
Assay validation using reference ligand(s)
Kd or EC50 estimate in agreement with other assays (e.g. primary assay, SPR)
Similar Kd or EC50 values with label-free and dye-labelled protein or between two labelling approaches
Denaturation of target protein should abolish MST binding response
Competition with another reference ligand
Label-free MST
Intrinsic fluorescence from target protein tryptophan residues 
Excitation 280 nm; emission 350 nm
MST using labelled target
Red, blue or green fluorescent dye covalently bound to the target protein by thiol 
(cysteine), amine (lysine) coupling or bound to polyhistidine tag of the protein
Excitation 493 nm; emission 521 nm (blue dye)
Excitation 557 nm; emission 574 nm (green dye)
Excitation 650 nm; emission 670 nm (red dye)
Selection of target protein concentration
Buffer optimisation 
(base buffer, pH, ionic strength, addition of detergent, protein carrier, polymers, etc.)
Choice of capillaries, LED power and MST power
Compound screening
DMSO tolerance test
Single concentration screening (optional)
8- or 12-point titration to derive Kd or EC50 estimate
Competition of hits with reference ligand(s)
Label-free pre-test
Selection of target protein concentration
No absorbance or background fluorescence 
from buffer or reference ligand(s)
Figure 2. MST assay development and screening workflow.
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because the label-free MST assay is too noisy or the refer-
ence compound exhibits UV fluorescence, Kd or EC50 val-
ues measured using two different labeling approaches can 
be compared instead. An example of this comes from a 
protein–protein interaction project in the ELF. The target 
protein was either covalently labeled to lysine residues via 
amine coupling or noncovalently labeled via its polyhisti-
dine tag using the tris-NTA dye. Titration of the unlabeled 
binding partner yielded similar EC50 estimates when using 
both labeling techniques, which were also in agreement 
with the AlphaScreen primary assay.
A key criterion to consider when deciding between 
labeled and label-free MST is the range of affinities that one 
aims to detect. When screening fragments or HTS hits with 
affinities in the micromolar or millimolar range, both 
approaches are generally applicable. However, during a 
hit optimization program, where compounds can demon-
strate low nanomolar affinities, label-free MST is unlikely 
to be suitable due to the relatively high protein concentra-
tions needed for this approach. To select a suitable concen-
tration of target protein, fluorescence is measured for a 
series of concentrations (usually three are sufficient). A 
concentration-dependent fluorescence signal is expected, 
and the lowest protein concentration yielding >200 counts 
using the nanodetector or >2500 counts using the UV detec-
tor is required for continued assay development (Fig. 3A). 
The minimum protein concentration suitable for label-free 
MST depends predominantly on the number of tryptophan 
residues. Seidel et al. reported that a protein with an average 
of two or more tryptophans could be used in concentrations 
down to 100 nM, enabling the accurate quantification of Kd 
values equal to or greater than 50 nM.45 However, the loca-
tion of the tryptophan residues within the protein and their 
local environment dictates the fluorescence efficiency, 
meaning that some proteins require much more than two 
tryptophan residues to yield a suitable fluorescence signal. 
In our experience, 150 nM of a protein containing seven 
tryptophans can provide a satisfactory signal-to-noise ratio. 
In contrast, we find that a concentration of dye-labeled pro-
tein of 15–50 nM is generally sufficient to provide a suit-
able signal, and have been able to use as low as 5 nM for 
some targets. It should be noted that the protein concentra-
tion optimization step is generally not needed when using 
the tris-NTA labeling kit, as the commonly used 6xHis tag 
binds one dye molecule and a 50 nM final concentration of 
protein yields a suitable fluorescent signal.39,44 This 1:1 
stoichiometry and the reversible equilibrium binding nature 
of the dye–His tag interaction also eliminate the free-dye/
purification step that is necessary for lysine and cysteine 
labeling procedures. For label-free MST, the pretest is car-
ried out to select the optimal protein concentration, but the 
assay buffer and reference ligand should also be tested to 
ensure that neither absorbs nor emits fluorescence at the 
tryptophan wavelengths. This is because the label-free 
capillaries are thinner and the detector is very sensitive to 
interference.
Buffer Optimization
For all assays, the buffer composition dictates the ability to 
detect ligand–protein interactions.46,47 Most common buffers 
are well tolerated in MST, and we ideally aim to maintain buf-
fer consistency with the primary biochemical assay used 
during the HTS; however, we have observed that alterations to 
the buffer are sometimes required to validate our MST assays. 
This is because base buffer, pH, and ionic strength can all influ-
ence the thermophoretic movement of molecules and dramati-
cally change their MST binding characteristics. Additionally, 
some buffer components interfere with dye fluorescence and 
will need to be removed or replaced. These buffer alterations 
must be conducted carefully and not overly compromise the 
known structure and function of the target, such as the require-
ment for magnesium or manganese ions for ligand binding to 
kinases or the presence of cofactors or nonprotein organic 
coenzymes, such as NADP+, NAD+, or coenzyme A, neces-
sary for certain enzymes, such as oxidoreductases.47 Similarly, 
if the target protein naturally forms disulfide bonds between 
cysteine residues, the inclusion of reducing agents such as 
beta-mercaptoethanol, tris(2-carboxyethyl)phosphine (TCEP), 
dithiothreitol (DTT), or l-glutathione (GSH) should be 
avoided, whereas for cytosolic proteins the presence of reduc-
ing agents is mostly beneficial in maintaining a reducing envi-
ronment to avoid the formation of nonnative disulfide bridges, 
which can lead to protein misfolding.48,49 Detergents such as 
Tween 20 and Pluronic F-127 have been shown to greatly 
increase the UV fluorescence of MST samples, not due to 
intrinsic fluorescence, but rather by preventing a reduction in 
the in-solution concentration due to adherence to the sample 
capillaries or the plasticware the samples come into contact 
with prior to capillary loading.50 This can be further mitigated 
by using microtiter plates with nonbinding surfaces and capil-
laries that are coated with polymers that minimize protein 
sticking. The use of detergents, however, should be carefully 
assessed during the label-free pretest, as they can introduce 
background UV fluorescence, which can adversely affect the 
assay. In our experience, Tween 20 causes a slight increase in 
UV background, but NP40 detergent should be avoided com-
pletely, as it saturates the UV detector. The addition of poly-
mers such as 0.1% PEG-8000 can prevent protein adsorption 
and sample aggregation, and a low concentration of reducing 
agent can also help prevent sample aggregation. Carrier pro-
teins like bovine serum albumin (BSA) cannot be used for 
label-free MST, as BSA contains tryptophan residues and 
greatly interferes with the signal. It can be used for labeled 
MST, but one needs to be cautious in assessing the potential 
effects of BSA on the binding response. Indeed, Scheuermann 
et al. observed an artifact in the presence of 0.01% BSA char-
acterized by a reversal in the direction of the sample’s 
Rainard et al. 231
Figure 3. Representative data collected during MST assay development. (A) UV fluorescence capillary scan for label-free pretest with 500 
nM (capillaries 3 and 4), 250 nM (capillaries 5 and 6), and 100 nM (capillaries 7 and 8) target protein. Protein storage buffer (capillary 2) and a 
high concentration of reference ligand (capillary 9) are also tested for fluorescence and compared with distilled water (capillary 1). (B) With 
no protein adsorption onto the capillaries, all capillary shape graphs overlay perfectly (top panel). Wide peaks and a lack of superimposition 
of the capillary shape graphs indicate unspecific protein adsorption to capillary walls (bottom left panel). Very strong adsorption of samples 
to the capillaries is characterized by a wide double peak (bottom right panel). (C) Typical MST traces for a compound showing positive 
thermophoresis (left panel) and a compound showing negative thermophoresis (middle panel). Compounds were titrated using a twofold 
dilution series starting at 500 µM (compound in blue) and 60 µM (compound in red), with 15 nM lysine-labeled target protein in buffer 
as recommended by NanoTemper (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, and 10 mM MgCl2 + 0.05% Tween 20) using standard 
capillaries. Measurements were performed using the nanodetector with 40% LED excitation power, 40% MST power, and 5 s MST on-time. 
Normalized binding response (Fnorm) of compounds showing positive (red) and negative (blue) amplitudes (right panel). (D) Capillary scan 
showing compound-induced changes in protein fluorescence (top left panel). Example of a compound causing a concentration-dependent 
variation in fluorescence greater than 10% across a series of capillaries (top right panel). MST traces showing a compound causing a decrease 
in baseline fluorescence (bottom left panel in white). In such an occurrence, the baseline data should be used rather than the T jump and/or 
thermophoresis data (shown in grey) to assess compound binding (bottom right panel).
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thermophoresis at micromolar concentrations of a partner pro-
tein, as well as a concentration-dependent decrease in raw 
fluorescence of the labeled target protein. It seems that 
rather than acting as a passive carrier, BSA was interacting 
with the titrated protein partner to form another population 
of binding complexes.50
We presently conduct a limited buffer optimization, ini-
tially comparing the buffer recommended by NanoTemper 
(50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 10 mM MgCl2, 
and 0.05% Tween 20) with that used for the primary HTS 
assay. We then assess the effect of adding/removing deter-
gents and adjusting a couple of key components, such as salt 
and the reducing agent concentration. If we find that an alter-
native buffer composition shows better MST binding 
responses, we test this buffer in the primary assay to check 
whether it has compromised the activity of the target protein. 
If the assay remains active, we then retest the hit compounds 
in the biochemical assay to check if the altered buffer has any 
effect on their activity before testing them in MST. Looking 
to the future, we aim to develop a more comprehensive pro-
cess for identifying the optimal MST buffer for each target. 
This would consist of experiments comparing the effects of 
pH, salt concentration, detergents, reducing agents, and pro-
tein carriers, separately or in combination. The significant 
complexity that this multifactorial approach introduces is not 
best tackled in a traditional linear experimental fashion, that 
is, adapting one variable per experiment. Rather, a more effi-
cient design of experiments (DoE) approach would be prefer-
able, whereby powerful statistical software and liquid 
handling automation are employed to create a matrix of vary-
ing buffer conditions and the data are analyzed for a maximal 
signal. This then facilitates iterative design of follow-up 
experiments to rapidly establish the optimal conditions. For a 
more in-depth review of DoE, see Tye.51
Choice of Capillaries, LED Power, 
MST Power, and Data Analysis
It is important to check that the protein and reference ligands 
do not adsorb to the walls of the sample capillaries, as this 
adversely affects the MST signal and can reduce or ablate 
apparent ligand binding due to loss of material. This is gen-
erally assessed for protein alone in an initial capillary shape 
scan (Fig. 3B). The capillaries are available as either stan-
dard or premium, the latter of which are coated with a pro-
prietary polymer surface that can greatly minimize protein 
or ligand adsorption to the capillary walls. We typically 
start by assessing the standard capillaries, and if there is 
significant protein adsorption after attempting to optimize 
the buffer, then we assess the premium-coated capillaries. 
Care should be taken, as sample adsorption can change 
upon addition of ligand, especially if the ligand is a protein 
or peptide with the potential to adsorb onto the capillaries 
when titrated at high concentrations.
There are two significant variables that can be manually 
adjusted on the MST system, LED power and MST power. 
The adjustment of these two variables can have very signifi-
cant impacts on the ability to observe target–ligand binding 
and the data quality, so they must both be carefully assessed. 
Increasing the excitation power of the LED light source 
increases the sample fluorescence, which is useful in reduc-
ing the protein concentration but must be balanced against 
the potential for photobleaching. Increasing the MST 
power, corresponding to the IR laser power, increases the 
temperature gradient from 2 to 6 °C. At higher MST power, 
the fluorescence decrease and thermophoretic movement 
are usually greater, and this greater signal change can aid in 
the resolution of binding events. Increasing the MST power 
must be considered carefully, as excessive exposure of the 
biomolecules to focused heat can lead to differences in sam-
ple density and convective flow, characterized by aberrant 
MST traces with a fluorescence increase toward the end of 
the measurement time. To some extent, this is mitigated 
against by alterations in the period during which the IR 
laser is turned on, also called the MST on-time, which is 
shorter at high MST power (only 2 s vs. 5 s for medium 
MST power and 20 s for low MST power), but good prac-
tice is for low or medium MST power to be used where 
possible and high MST power only attempted if the binding 
response displays a very low signal-to-noise ratio. 
Regardless of the MST power, the MST measurement time 
should be set to at least 10 s to allow for the detection of 
aggregation.
In a typical MST measurement, a 5 s fluorescence base-
line is first measured. Upon turning on the laser, IR radia-
tion is absorbed by the water molecules, producing an 
immediate increase in temperature and a rapid quenching of 
fluorescence (T jump). This is followed by the thermopho-
resis phase, typically lasting 10–20 s, where the fluorescent 
molecules diffuse away from (positive thermophoresis) or 
toward (negative thermophoresis) the heat focus. The direc-
tion and rate of thermophoresis are dependent on the prop-
erties of the fluorescent molecules, meaning that the 
ligand–protein complex moves faster or slower through the 
temperature gradient than the unbound protein. Switching 
off the laser leads to an inverse T jump and reequilibration 
of the sample (Fig. 3C). To calculate equilibrium binding 
constants, the MST trace of each capillary is analyzed for 
the difference between the baseline fluorescence, also 
referred to as Fcold, and the fluorescence level during the T 
jump or thermophoresis phases, known as Fhot. The normalized 
fluorescence (Fnorm) is defined as Fhot/Fcold and expressed as 
parts per thousand. Fnorm values are plotted against the 
ligand concentration in a concentration–response curve to 
provide an estimate of affinity (Fig. 3C). Binding curves 
can also be displayed using ∆Fnorm (baseline-corrected nor-
malized fluorescence) or fraction bound (where all ∆Fnorm 
values are divided by the curve amplitude) to account for 
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differences in baseline fluorescence or response ampli-
tude.26,42 Two models are available to fit the data in 
NanoTemper’s MO.Affinity Analysis software: a Kd model 
for binding interactions with a predicted 1:1 stoichiometry 
and a Hill model to fit multivalent interactions with higher 
stoichiometry or interactions with known cooperativity and 
a slope coefficient different from 1. This model will derive 
an EC50 estimate, rather than a Kd. The MST analysis rou-
tine described above should only be applied to data where 
the ligand does not directly influence the baseline fluores-
cence of the protein. When the ligand causes >10% varia-
tion in protein initial fluorescence, then as long as the ligand 
is not itself fluorescent or acting as a quencher (i.e., the 
ligand is causing conformational changes in the protein that 
change the exposure of fluorescent residues or labels), 
direct analysis of the baseline fluorescence can be used to 
estimate affinity (Fig. 3D).
Assay Validation with Reference 
Ligand
A critical assessment of the suitability of an MST assay to be 
used to follow up hits from an HTS campaign is that the affin-
ity estimates of known reference ligands are in agreement with 
those obtained using other techniques, particularly the primary 
screening assay. Most hits from HTS exhibit affinities in the 
micromolar range and are typically tested at maximum con-
centrations of 10–30 µM. The consequence of this will be that 
a technique that demonstrates a reduction in sensitivity of as 
little as twofold will be unlikely to confirm the activity of 
many of the hits. The ideal situation is to have a collection of 
structurally diverse small-molecule reference compounds with 
varying affinities against the target. This would best model the 
situation of testing a diverse set of hits from HTS. In reality, 
many ELF targets do not have a selection of small-molecule 
references, particularly for novel targets aiming to identify tool 
compounds for the first time. If no compounds are available, 
then alternatives are typically sought to act as reference ligands, 
such as enzyme substrates, peptides, or nucleic acid oligomers. 
As mentioned, multiple reference ligands with varying affini-
ties are preferred to ensure that the MST assay not only exhib-
its a sensitivity similar to that of other techniques, but also 
detects a similar rank order of affinity. More often than not, 
however, only one or two reference ligands are available. Each 
reference molecule is checked for quenching or autofluores-
cence by testing the highest concentration of compound on its 
own. Alternatively, absorbance and fluorescence spectral scans 
are performed using a monochromator on a multilabel reader, 
a cheaper and quicker alternative method that we use to pre-
screen large numbers of hit compounds. Additionally, a simple 
binding test is carried out on a single concentration of refer-
ence ligand in the presence and absence of protein to determine 
if the bound and unbound ligand complexes display an accept-
able signal-to-noise ratio greater than 3. A full titration of the 
ligand then provides the affinity of the interaction. Importantly, 
the titration of the reference ligand should not lead to an 
increase in sample adsorption to the capillaries, since this can 
be mistaken for a concentration-dependent increase in signal. 
It is therefore important to check the capillary shape overlays 
for signs of sample adsorption. Once the samples are loaded 
into the capillaries, we usually measure the MST signal at dif-
ferent time points, immediately after the sample is loaded and 
then again after 30 and 45–50 min. This is to ensure that the 
binding has reached equilibrium and the affinity will not be 
underestimated, that there is no change in capillary adsorption 
over time, and that the signal from the binding complex is sta-
ble and consistent across the 45–50 min period required to 
screen at the maximum capacity of 96 capillaries. The esti-
mated Kd or EC50 values for the reference ligands should be in 
agreement with reported data and, importantly, similar to those 
obtained in the primary assay.
A denaturation test is often used to provide evidence that 
the reference ligand–target MST binding response is specific 
to structurally intact protein. For this, the target is denatured in 
a 2% sodium dodecyl sulfate (SDS) and 20 mM DTT solution 
and heated to 95 °C. As mentioned previously, for targets 
labeled with the His tag dye, a His-peptide control is used to 
check for interference of dye–tag binding. Another control 
experiment for confirming binding specificity is to titrate the 
ligand against a protein it should not interact with, such as a 
version of the target where key binding site residues have been 
mutated, or an unrelated protein. Unfortunately, due to the 
limitations in protein construct availability, we do not usually 
have access to a mutated version of the target protein for the 
ELF projects. When more than one reference molecule is 
available, and they are known to bind in the same region of the 
target, then competition experiments are a very useful tool. 
Alternatively, titrating the unlabeled version of the target pro-
tein to compete for reference ligand binding to the labeled pro-
tein can also be quite informative.
Compound Screening
When working with ligands or test compounds dissolved in 
organic solvents, it is important to determine what effect 
solvent has on the assay. Our compounds are stored in 4 or 
10 mM stock solution in 100% DMSO. DMSO can reduce 
protein stability and/or functionality, so it is important to 
ensure that the final DMSO concentration in test samples 
will not have a detrimental effect on the protein or on the 
quality of the data generated.52,53 We usually test com-
pounds at a top concentration of 40 or 100 µM (4–10 times 
the primary screening concentration) and aim to keep the 
final DMSO concentration below 5%. A DMSO tolerance 
test on the labeled target protein indicates the maximum 
concentration suitable for testing and involves comparing 
the MST data for three to four capillaries with labeled pro-
tein only versus labeled protein plus varying concentrations 
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of DMSO. All quality parameters are compared to ensure 
that the DMSO does not have a negative effect on the target 
protein fluorescence (Fnorm), quality of the MST traces, sur-
face adsorption, photobleaching, or sample aggregation. In 
some cases, the presence of 1% or 2.5% DMSO actually 
leads to an increase in thermophoretic movement.
Depending on the number of compounds being tested, the 
amount of available reagents, and the stage in the triage pro-
cess, compounds are tested in MST as either a single concen-
tration (usually in triplicate capillaries to provide three 
technical replicates) or as a full titration comprising either 8 
or 12 concentrations, which allows for two to three com-
pounds per capillary chip. For single-concentration testing, 
MST data are analyzed relative to positive (e.g., a concentra-
tion of reference ligand yielding saturation in a full binding 
curve) and negative (sample with DMSO only) controls. As 
mentioned previously, different ligand–protein complexes 
can produce both negative and positive thermophoresis. 
Because of this, we do not apply double referencing to the 
negative and positive controls; rather, we apply a statistical 
differentiator of three standard deviations on either side of 
the mean negative control only. The hits are then tested in a 
full 8- or 12-point titration. It is important to apply a consis-
tent data analysis routine across all of the hits, for example, 
using the same Fcold and Fhot regions of analysis and the same 
curve-fitting algorithm for all MST traces. In addition to the 
quantitative data, we also employ a qualitative scoring sys-
tem to classify the compounds screened by MST. This is use-
ful to inform triage decisions, as an affinity estimate (Kd or 
EC50) cannot always be determined for weak binders, and it 
allows an expert user assessment of the quality of the data to 
be captured in our database. A similar scoring system, which 
ranges from 1 to 6, is used when assessing SPR and TSA 
data. The score is a qualitative assessment of the likelihood of 
binding, with compounds scoring 1 if they produce data simi-
lar to or better than the reference molecule. Compounds with 
scores of 2, 3, and 4 present a sliding scale whereby there is 
more uncertainty of the response, less potency, more noise, or 
reduced amplitude. Compounds scoring 5 display bumpy and 
noisy traces that are characteristic of aggregators, and if no 
indication of binding is observed, then the compound scores 
a 6. As our data scoring is subjective, we have introduced a 
system whereby at least two scientists independently score 
the data and then discuss their results. Due to the irreversible 
nature of our triage process, if there is disagreement between 
the two, then a compromise score is accepted or a third scien-
tist breaks the deadlock.
ELF Experience
As mentioned previously, the ELF portfolio is diverse and 
consists of targets from many well-known target classes, as 
well as from many unprecedented target classes. The targets 
cover many different molecular weights, structures, and 
functions, and where possible, we attempt to establish at 
least one predictive biophysical assay in the form of MST, 
SPR, or TSA. These three technologies have been acquired 
over time, so many targets have not been tested against all 
three, and indeed, for some targets we do not attempt one or 
more of the assays, as we deem them inappropriate, for 
example, very large molecular weight targets with SPR. 
That said, some interesting observations arise from analyz-
ing the differing assay development success rates across the 
three technologies, success being defined as establishing a 
robust, reproducible assay validated with known reference 
ligands and capable of screening hit molecules from the 
HTS (Fig. 4A). We observe similar success rates with MST 
and SPR, which may seem low at 47% and 42%, respec-
tively, but this is bearing in mind that the proteins are prin-
cipally provided by the target owner as an aliquot of the 
screening batch, which has been produced with the bio-
chemical assay as the main focus. These are often pro-
vided in inappropriate storage buffers, not compatible 
with dye labeling or immobilization procedures, and 
require buffer exchange with associated freeze–thawing 
cycles. Additionally, the reference molecules are some-
times poorly validated in the literature or the target owner’s 
hands or appear to be nonspecific binders, such as aggrega-
tors or denaturants, when we come to test them. We are 
almost always only provided with one construct, and 
undoubtedly, careful construct design and testing would 
improve success rates; however, this would be a very 
resource-intensive exercise for target owners and is currently 
out of scope for our own activities. Interestingly, TSA has a 
considerably higher success rate at 64%, which likely reflects 
the technical simplicity of this technology and that it does not 
require covalent modification or immobilization of the pro-
tein. When looking at MST assay development success rates 
broken down by target class, we found the greatest success 
with cAMP binding proteins (100%) and protein–protein 
interaction targets (60%), but had less success with enzymes 
(38%) and protein–nucleic acid interaction targets (33%) 
(Fig. 4B). For this last class, we have been reliant on observ-
ing changes in MST upon binding of unlabeled oligonucle-
otides to labeled proteins to validate the assays, which has not 
been particularly successful. Interestingly, we often observe 
very good changes in MST by orientating the assay the other 
way around, that is, with unlabeled protein binding to labeled 
oligonucleotides. An assay set up in this format can be used 
to provide indirect evidence of target engagement by appar-
ent competition of binding to the protein and is also very use-
ful to identify RNA/DNA intercalators but does not provide 
direct evidence of target engagement, which is far more pref-
erable. Usefully for us, targets that fail when using one tech-
nique typically work with one of the others, and overall we 
manage to enable 72% of the projects with one or more bio-
physical assays. The following are a couple of case studies 
detailing how MST has been applied to ELF projects.
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Case Study: Using MST and TSA to 
Triage Bacterial Kinase Screening Hits
The molecular target, a bacterial kinase that is essential for 
gram-negative bacteria survival with currently no known 
small-molecule inhibitors, was screened against the JECL 
comprising 445,917 compounds in a biochemical ADP 
Hunter Plus (DiscoverX, Fremont, CA) assay format. A 
total of 955 compounds, consisting of statistically signifi-
cant hits from the HTS and potential false-negative com-
pounds rescued using Bayesian modeling, were tested for 
confirmation of activity as dose–response curves. Of these, 
an IC50 of 20 µM or below was calculated for 73 com-
pounds. To identify the most promising of the 73, they were 
tested for correct molecular identity and acceptable purity 
with liquid chromatography–mass spectrometry (LC-MS), 
and were also tested in TSA and MST.
For the MST assay development, the workflow described 
previously and shown in Figure 2 was followed using the 
red dye/His tag labeling approach. A concentration of 50 nM 
His tag–labeled protein yielded a suitable fluorescent signal 
when applying 40% LED excitation power, 40% MST 
power, an MST on-time of 5 s, and an MST measurement 
time of 10 s. Slight protein adsorption was observed in stan-
dard capillaries, which was reduced with premium-coated 
capillaries. The buffer comprised 15 mM HEPES, 20 mM 
NaCl, 10 mM MgCl2, and 0.05% Tween 20 (pH 7.4), the 
same as that used in the primary assay minus bovine gamma 
globulin, to simplify the buffer, and EGTA, which cannot be 
used with His tag labeling due to the requirement for Ni2+ in 
the His–NTA interaction. The target protein was tolerant to 
≤2.5% DMSO. No small-molecule reference was available 
to validate the assay, so binding of both the (nonpeptide) 
phosphate acceptor substrate and ATP was investigated. 
Binding of the phosphate acceptor substrate was measured at 
0, 30, 60, and 120 min postloading into the capillaries to 
check that equilibrium was reached and ensure consistency 
and stability in data acquisition during a 45 min screening 
run. The data showed no sample adsorption onto capillaries 
over time, but the MST traces appeared less noisy after 30 
min incubation than at time zero and the response amplitude 
was almost double (26.7 amplitude at time zero, 50.9 at 30 
min, 54.8 at 60 min, and 53.6 at 120 min). The Kd of the 
substrate at time 0 min was 3.9 ± 1.9 µM (mean ± SD, N = 
3), which is similar to the reported Km of 6.8 µM; however, 
the consequence of the increased amplitude over time was 
that the Kd was three- to fivefold higher from 30 min onwards 
(18.2 ± 3.1 µM after 30 min, 17.1 ± 2 µM after 60 min, and 
13.4 ± 1.9 µM after 120 min). This suggests that, at least for 
the phosphate acceptor substrate, it takes up to 30 min before 
the system reaches full equilibrium (Fig. 5A). Due to the dif-
ference in Kd values at 0 min and after 30 min, this ligand 
was used as a reference throughout screening at the start and 
at the end of each 45 min run. ATP binding was also investi-
gated; however, no binding was apparent in a variety of buf-
fers, in the presence of the phosphate acceptor substrate, 
when using ATP from at least three different suppliers or 
with Mg2+-ATP. This is in contrast to TSA, where shifts in 
the thermal melting temperature (Tm) of +6 °C were observed 
for both substrates. This suggests that this MST assay may 
not be suitable for confirming the binding of orthosteric 
ATP-competitive inhibitors. In an ideal situation, this ques-
tion about the sensitivity and specificity of the assay would 
be further addressed by using a range of reference com-
pounds of various binding modes. This would provide the 
most comprehensive assessment of how the assay should be 
employed and how rigidly or not to interpret negative or 
positive results. Unfortunately, no reference compounds 
have been identified for this particular bacterial kinase to 
make such an assessment.
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Figure 4. Success rates for developing biophysical assays. (A) Developing MST, SPR, and TSA exhibits different rates of success. (B) 
Number of successful and unsuccessful MST assays developed according to their target class.
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The screening hits were tested in MST at a single con-
centration of 40 µM in triplicate using the conditions estab-
lished during assay development, with positive (substrate) 
and negative (DMSO) controls included at the start and at 
the end of each run. MST data were analyzed using the 
MO.Affinity Analysis software, and an unpaired t test con-
firmed that the normalized fluorescence signal (Fnorm) of the 
positive control (75 µM phosphate acceptor substrate) was 
statistically different from that of the negative control (1% 
DMSO), with a p value lower than 0.0001. A statistical cut-
off of three standard deviations either side of the mean neg-
ative control was applied, with 36 out of 73 hits showing a 
positive MST response. The 36 compounds were subse-
quently tested as an 8-point twofold dilution series with a 
maximum concentration of 100 µM. The data for each com-
pound were scored from 1 to 6 for likelihood of binding 
Figure 5. Case study 1: Hit selection for a bacterial kinase target using MST and TSA biophysical assays. (A) Normalized MST 
binding response (∆Fnorm) of phosphate acceptor substrate (150 µM to 73.2 nM) to 50 nM His tag–labeled protein kinase measured 
immediately (closed circles) and 30 min (open circles), 60 min (closed squares), and 120 min (open squares) after sample loading. 
(B) Venn diagram showing distribution and overlap of hits from the primary biochemical assay and MST and TSA biophysical assays. 
Representative MST traces (left panel) and normalized binding response (right panel) for compounds given scores of (C) 1, (D) 2, (E) 
3, (F) 4, (G) 5, and (H) 6. DRC = dose–response curve.
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with 16 likely/possible binders scoring between 2 and 4, 5 
aggregators scoring 5, and 15 nonbinders scoring 6 (Fig. 
5C–H).
The strategy of testing all compounds with MST as a 
single concentration prior to determining the affinity of the 
actives was mentioned before and has been described in the 
literature.32 In that case, the compounds were tested in 
duplicate, as recommended by NanoTemper for single-
point screening. Martin et al. screened 1700 fragments at a 
concentration of 500 µM and identified 124 hits with an 
MST signal out-with two standard deviations of the nega-
tive DMSO control;32 however, they did not confirm hit 
activity with full dose–responses in MST; rather, they vali-
dated 38 of the 124 hits in an orthogonal biophysical tech-
nique, heteronuclear single quantum coherence (HSQC) 
NMR. A second report of fragment screening using MST, 
from Linke et al., describes testing a library of 193 com-
pounds as a 12-point twofold dilution series with a maxi-
mum concentration of 10 mM. They then retrospectively 
analyzed the ∆Fnorm data for the 150 µM data point to esti-
mate if single-concentration screening would have been 
sufficient to identify the hits. They concluded that this sin-
gle-point screen would have been predictive in identifying 
the hits, which they later confirmed with x-ray crystallogra-
phy.31 Our own experience has been slightly different in that 
only 21 of the 36 MST hits (58%) from the single-concen-
tration screening strategy confirmed activity when tested as 
dilution series, despite having initially been tested in tripli-
cate. This relatively low confirmation rate was a concern, so 
we tested the 37 “inactive” compounds as dilution series, 12 
of which surprisingly appeared to be potential binders (32% 
scoring 1–4). It may have been that a cutoff of three stan-
dard deviations from the mean negative control was too 
stringent, so we reanalyzed the single-point data based on 
two standard deviations from the mean, which would have 
identified 6 of the 12. This still leaves six compounds, 
which we would class as being probable/potential binders, 
which were not identified using a single-concentration 
screening strategy and two standard deviation selection, 
providing a false-negative rate of 8%.
The 73 compounds were also tested in TSA at a single 
final concentration of 40 µM. Briefly, compounds were 
tested in the presence or absence of 1.36 µM target protein, 
with 1× Protein Thermal Shift dye (Applied Biosystems, 
Waltham, MA; excitation 570 nm, emission 591 nm) in 
assay buffer (15 mM HEPES, 20 mM NaCl, and 10 mM 
MgCl2 [pH 7.4]). Controls for “no protein” and 1% DMSO 
(corresponding to the final DMSO concentration found in 
the compound samples) were also included during screen-
ing. Protein unfolding was induced by increasing the sam-
ple temperature from 25 to 99 °C, with increments of 0.05 
°C per second, a scan rate selected to maximize screening 
efficiency while not adversely affecting the quality of the 
data. Data were analyzed using the derivative method in the 
Protein Thermal Shift software from the QuantStudio 5 
instrument (Applied Biosystems). A difference in target 
protein melting temperature in the presence of compound 
(∆Tm) of >1.5 °C was considered significant, as it was out-
side the 95% confidence intervals of the protein-/vehicle-
only control, indicating that the compound had a stabilizing 
effect on the target protein and was likely to be a binder.
Figure 5B shows a Venn diagram representing the number 
of compounds reporting as active in the various assays. Three 
compounds were recognized as binders by both technologies. 
TSA identified nine compounds that significantly enhanced 
the stability of the target protein with ∆Tm values between 1.7 
and 10.2 °C, but did not show a binding response in the MST 
assay. Conversely, 25 compounds that displayed a concentra-
tion-dependent MST binding response did not positively 
affect the target protein’s melting temperature in the TSA. 
Taken together, these results demonstrate that one biochemi-
cal and two biophysical techniques can identify distinct and 
overlapping populations of hits. Having this diversity of data 
allows for more informed decision making when selecting the 
final QHL, particularly when combined with the assessment 
of the compound structures, analytical results, and legacy 
screening data for the hits. The fact that hits from a biochemi-
cal screen produce variable responses in different biophysical 
assay formats will be familiar to most screening laboratories, 
and there are published examples of the phenomenon. 
Schiebel et al. describe the parallel screening of 361 frag-
ments against endothiapepsin in four different biophysical 
techniques (MST, TSA, saturation transfer difference spec-
troscopy nuclear magnetic resonance [STD-NMR], and elec-
trospray ionization mass spectroscopy [ESI-MS]), where they 
found a diversity of hit populations, with those identified by 
MST being more distinct than those identified in the other 
techniques.23 Martin et al. also found that their MST fragment 
screen on BRD9 identified a number of hits, later validated by 
NMR, which were not identified by DSF or SPR, indicating 
the importance of pragmatism and employing a diversity of 
techniques to inform hit selection.32 The process of validation 
of the hits from the bacterial kinase screen is currently ongo-
ing, with resynthesis and testing with lower-throughout tech-
niques such as NMR, ITC, and x-ray crystallography in an 
attempt to rationalize the different compound profiles across 
the different assay formats.
Case Study: Using MST to Validate 
and Characterize Inhibitors of a 
Protein–Protein Interaction Target
As mentioned before, 15% of the ELF portfolio consists of 
protein-protein interaction targets that are typically difficult 
to drug due to the large, often quite shallow interaction sur-
faces between proteins, which can lead to a high proportion 
of false positives when screening.54–56 A protein-protein 
interaction target was screened against the JECL (318,132 
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compounds at that time) at 10 µM using an FP binding assay 
to measure the ability of compounds to compete with a fluo-
rescently labeled peptide. From 1200 compounds initially 
identified as hits (hit rate = 0.38%) and 271 structurally 
similar compounds identified via Bayesian modeling, 377 
compounds were confirmed as active. These were then 
tested for potency in the primary assay and for redox reac-
tivity, a key criterion to avoid in the target product profile. 
Compounds showing redox activity or fluorescence inter-
ference in the FP assay were deselected, leaving 20 com-
pounds that were submitted for analytical assessment, 
visual inspection, and legal clearance, resulting in a QHL of 
8 compounds.
For this target, the rapid exclusion of interference or 
undesirable compounds during the screening cascade meant 
that biophysical assays were not required prior to nomina-
tion of the QHL; however, in a busy portfolio, with compet-
ing priorities and limited resources, committing to a 
program of chemistry requires convincing orthogonal evi-
dence of target engagement. There were also questions 
raised around some of the compounds on the QHL, which 
contained a known fluorescent moiety, which it was felt 
may have an effect on the FP assay. We therefore estab-
lished a label-free MST assay to characterize the QHL com-
pounds. Pretests were performed using the unlabeled target 
protein and the UV detector to select a suitable concentra-
tion of labeled protein. Premium-coated and standard 
treated MST capillaries were compared to assess protein 
adsorption to the capillary walls. Unlabeled target protein 
(100, 200, and 500 nM) yielded signals of 2500 fluores-
cence units or more and did not show adsorption to either 
capillary type when using 50 mM HEPES buffer (pH 7.5) 
with 300 mM NaCl and 0.1% Pluronic F-127. Measurements 
were performed using 10% LED excitation power, 40% 
MST power, an MST on-time of 5 s, and an MST measure-
ment time of 10 s. Those conditions were used in subse-
quent experiments with 150 nM protein. The label-free 
pretest also included assessing compound autofluorescence 
at the tryptophan wavelength, which identified UV auto-
fluorescence for two of the QHL compounds.
Of the eight QHL compounds, two structurally related 
hits showed a positive concentration-dependent binding 
response in the MST assay, five did not show any binding, 
and one displayed an aggregator profile. Both active mole-
cules also showed a concentration-dependent decrease in 
initial fluorescence, meaning that the raw fluorescence data, 
and not the MST data, were analyzed to generate a binding 
curve (Fig. 6A). To ensure that this response was not due to 
a fluorescence artifact, particularly because these were the 
two compounds containing the known fluorescent moiety, it 
was essential to perform an SDS denaturation test. The 
MST signal of both compounds was abolished after dena-
turation of the target protein in 2% SDS/20 mM DTT and boil-
ing for 5 min at 95 °C, indicating that the observed decrease in 
protein fluorescence was not simple fluorescence quenching, 
but rather a specific effect on the structurally intact 
protein.
Both compounds were resynthesized and their affinities 
in the FP and MST assays were in agreement with those 
Figure 6. Case study 2: Hit characterization for a protein–
protein interaction target. (A) MST binding response for one of 
the hit compounds from 40 µM to 19.5 nM compound vs. 150 
nM unlabeled protein. Measurements were performed using the 
UV detector with 10% LED excitation power, 40% MST power, 
and 5 s MST on-time (Kd ± SD = 14.3 ± 3.0 µM). (B) Compound 
binding tested alone (closed circles) or with 3 µM (open circles), 
10 µM (closed squares), or 30 µM (open squares) reference 
peptide. (C) The R-enantiomer binds (closed circles), while the 
S-enantiomer does not (open circles).
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obtained with the screening samples from the JECL. The 
addition of increasing concentrations of a peptide mimic of 
the target’s binding partner resulted in increasing Kd values 
for both hit compounds (Fig. 6B), confirming that they both 
bind at the interface of the protein-protein interaction. The 
two hit compounds were also clearly competitive with a lit-
erature reference small molecule. Both compounds contain 
a chiral center, and separation of the R- and S-stereoisomers 
showed that only the R-stereoisomer binds the target (Fig. 
6C), providing chemical validation of the binding specific-
ity and further evidence that the MST response was not due 
to fluorescence artifacts.
Taken together, these results provided enough confidence 
to initiate a chemistry program that resulted in the preparation 
of more than 110 new analogs and led to ligand-bound crystal 
structures, which helped rationalize the SAR. The success of 
this project can be significantly attributed to the positive MST 
data, as it is unlikely that chemistry resources would have been 
applied based solely on the screening data.
Conclusions
In our experience, MST has proven to be a useful biophysi-
cal technique to apply to the triaging and characterizing of 
HTS hits. In the 2 years since implementing this technol-
ogy, we have found that it has improved the chances of suc-
cess for some programs by providing orthogonal evidence 
of target engagement that complements other biophysical 
techniques, such as SPR and TSA. On several programs, 
when SPR and TSA were unsuitable or the assay develop-
ment was unsuccessful, MST provided the only corrobora-
tive orthogonal biophysical data. Conversely, MST assay 
development sometimes failed when SPR and/or TSA 
worked well. The reasons for the inconsistency in develop-
ing assays with different techniques are likely many and 
varied. In one example from the ELF, a target construct 
exhibited a relatively low melting temperature of 32 °C, 
indicating that it was quite an unstable protein. It is likely 
that from heating the sample within the capillaries, or 
potentially even at room temperature, a substantial amount 
of the protein would have been in an un- or misfolded state, 
which prevented us from observing ligand binding. Indeed, 
the results from SPR showed that at ambient temperature, it 
was difficult to resolve ligand binding, yet conducting it at 
10 °C provided very good data. The temperature of the 
Monolith NT.Automated instrument can only be set to 25 °C, 
while the other NanoTemper Monolith instruments can be 
set to 25 °C or above, so the possibility of being able to 
lower the sample temperature may be useful in improving 
the success rate for developing assays when working with 
less stable proteins.
In our experience, a significant amount of the failure for 
MST (and SPR) assay development has been due to poorly 
validated reference molecules, particularly for new/difficult 
targets where high-quality, highly specific small molecules 
are not typically available. Ironically, this is one of the rea-
sons that such targets are being screened within the ELF, to 
find new targeted chemical probes, but this can present a 
chicken-and-egg problem, where the validation of new 
assays requires highly validated reference molecules, yet 
the validation of new molecules requires highly validated 
assays. Therefore, the availability of multiple reference 
molecules, ideally small molecules, rather than endogenous 
protein or peptide ligands or substrates, is likely to improve 
the chance of successfully developing an MST assay and 
using it productively in confirming the target engagement 
of small-molecule hits from an HTS campaign. The other 
key components to successfully employing MST are pro-
tein quality and the ability to access multiple protein con-
structs, allowing for the evaluation of multiple labeling 
techniques. This is a significant limitation to the ELF work-
flow, as we principally rely on collaborators to provide the 
proteins. Another area for improvement of our workflow 
would be the integration of our MST instrument with an 
automated liquid handling system, such as that described by 
Sanofi and NanoTemper,31 thereby increasing the through-
put, which might be able to more efficiently deal with the 
large numbers of hits that are identified when screening 
some targets.
As described here, we have observed some issues regard-
ing the reliability of MST single-point screening. It appears 
that generating full dose–response curves is the most com-
prehensive way of identifying genuine binders, but this has 
a detrimental effect on throughput and screen cost. More 
study will be required to optimize a screening workflow, 
and we intend to investigate approaches such as varying the 
number of points within a dilution series and whether any 
other variables affect the likelihood of false negatives in 
single-point screening, such as incubation times, buffer 
composition, or target class.
Like other researchers, we find that MST is best used in 
combination with other biophysical techniques, as they all 
tend to identify different populations of hits with sometimes 
little overlap. For this reason, we would recommend using 
multiple assays and technologies during a screening cam-
paign and assess hits within the context of the totality of the 
data, including biochemical and biophysical assay data, 
sample QC data, and structural assessment, when selecting 
the most promising hits.
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